Abstract: Provided is a method for manufacturing syngas including (S1) heat-treating organic wastes under hydrogen and a catalyst in a first reactor; (S2) separating the catalyst and the hydrogen from a product of (S1) and recovering a first mixed gas from which the catalyst and the hydrogen have been removed; (S3) reforming the first mixed gas recovered in (S2) with water vapor to form a product; (S4) separating carbon dioxide from a product of (S3) and recovering a second mixed gas from which the carbon dioxide has been removed; (S5) converting the carbon dioxide separated in (S4) into carbon monoxide through a reverse Boudouard reaction in the second reactor; and (S6) mixing the hydrogen separated in (S2), the mixed gas recovered in (S4), and the carbon monoxide converted in (S5) to produce syngas.

Abstract: Provided is a method for converting waste plastic pyrolysis oil into light olefins with a high yield. The method includes: (1) inputting waste plastic pyrolysis oil into a reactor; (2) allowing the waste plastic pyrolysis oil to react in the reactor in the presence of a catalytic cracking catalyst containing a first metal and a second metal to form a product; and (3) recovering light olefins by separating the catalytic cracking catalyst and oil from the product obtained in step (2).

Abstract: Provided is a method of manufacturing syngas including (S1) heat-treating organic wastes under a catalyst in a first reactor to produce a first mixed gas; (S2) separating the catalyst and carbon dioxide (CO2) from the first mixed gas, and recovering a mixed gas from which the catalyst and the carbon dioxide (CO2) have been removed; (S3) converting the carbon dioxide (CO2) separated in (S2) into carbon monoxide (CO) by a reverse Boudouard reaction in a second reactor; and (S4) mixing the mixed gas recovered in (S2) and the carbon monoxide (CO) converted in (S3) to produce syngas.

Abstract: An electroluminescent display device includes an electroluminescent display device includes a substrate; a first pixel row on the substrate including a first plurality of pixels arranged along a first direction; a second pixel row on the substrate including a second plurality of pixels arranged along the first direction, the second pixel row being spaced apart from the first pixel row in a second direction; a first groove between the first and second pixel rows; and a light emitting diode in each pixel of the first and second pixel rows, wherein the first groove includes a first portion at one end of the first pixel row, a second portion at the other end of the first pixel row and a third portion between the first and second portions, and wherein third portion is smaller than the first portion and greater than the second portion.

Abstract: Disclosed are: a method for measuring the expression level of an ERa or PR gene to provide information necessary for diagnosis of preterm birth; and a kit for diagnosis of preterm birth, the kit including a probe or primers for an ERa or PR gene and an antibody to an ERa or PR protein, so that reliable information for diagnosis of preterm birth can be simply and easily provided.

Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.

Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.

Abstract: Provided is a method for screening a composition for preventing or treating an osteoporosis and a metabolic bone disease using a TALLYHO/JngJ mouse, and more particularly, to a method for screening a compound effective in preventing and treating a disease caused by abnormalities of a bone metabolism including an osteoporosis, through assessment of a bone regeneration activity, such as acceleration of osteoblast differentiation, inhibition of osteoclast differentiation, variation of cytokine in a serum, as well as a bone mineral density and a bone mineral content in a femur, using a TALLYHO/JngJ mouse instead of a ovariectomized animal generally used in estimating the efficacy of a new osteoporosis medicine in an animal. The screening method has a simple and stable experiment procedure, and can be used in developing an agent for treating an osteoporosis of men and improving the bone mineral content.